AM Squared’s Biogen BIIB Stock Holding History

AM Squared’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$96.9K	Buy	500 +400	+400%	+$83.7K	0.21%	38
2024 Q2	$23.2K	Sell	100 -300	-75%	-$65.2K	0.06%	65
2024 Q1	$86.3K	Buy	+400	New	+$93.7K	0.21%	18

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AM Squared's BIIB Position: Q3 2024 in Review

AM Squared increased its Biogen (BIIB) stake by 400% in Q3 2024, buying an estimated $83.7K and bringing the position to 500 shares worth $96.9K. The position accounts for 0.21% of the portfolio, ranked #38.

AM Squared first reported a position in BIIB in Q1 2024 and has held it in 3 quarters since. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

AM Squared held 500 shares of Biogen worth $96.9K as of Q3 2024.
AM Squared bought 400 Biogen shares in Q3 2024, an estimated $83.7K.
Biogen made up 0.21% of AM Squared's portfolio in Q3 2024, its #38 holding.
AM Squared first reported a position in Biogen in Q1 2024 and has held it in 3 quarters since.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.